Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sutro Biopharma ( (STRO) ) has provided an announcement.
On June 20, 2025, Sutro Biopharma received a notice from NASDAQ indicating non-compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Market. The company has until December 17, 2025, to meet this requirement, with options for an additional compliance period if necessary. Failure to comply could result in delisting, but the company plans to monitor its stock price and may implement a reverse stock split to regain compliance.
The most recent analyst rating on (STRO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Sutro Biopharma stock, see the STRO Stock Forecast page.
Spark’s Take on STRO Stock
According to Spark, TipRanks’ AI Analyst, STRO is a Underperform.
The overall stock score for Sutro Biopharma is low, primarily due to significant financial challenges, including negative equity and cash flow deficiencies. Technical indicators further suggest bearish momentum, and valuation metrics reflect the lack of profitability. These factors contribute to a high-risk profile typical of early-stage biotech firms.
To see Spark’s full report on STRO stock, click here.
More about Sutro Biopharma
Sutro Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development of novel therapeutics for cancer and autoimmune disorders. The company is known for its proprietary cell-free protein synthesis platform, which is used to create complex biologics.
Average Trading Volume: 1,477,594
Technical Sentiment Signal: Sell
Current Market Cap: $67.47M
See more insights into STRO stock on TipRanks’ Stock Analysis page.